ClinicalTrials.gg
TerminatedNCT02685293Updated Aug 28, 2019Results posted

Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD

A Phase 3 interventional study of GFF MDI (PT003) and Placebo MDI in COPD, sponsored by Pearl Therapeutics, Inc.. Terminated at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-08-28.

Sponsored by Pearl Therapeutics, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Why this study was terminated
Lack of recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
71st of 73
4 · median 152
Started
2016
with 5 others
Phase 3
33 of 73
1 open now
Registered
52nd of 73
by date
Lead sponsor
18 of 73
Pearl Therapeutics, Inc.

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 71st largest by enrollment, is one of 6 that started in 2016, is one of 33 in phase 3, and was the 52nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, single-center, chronic-dosing (7 days), two-period, two-treatment, cross-over study to evaluate the treatment effect of PT003 compared with that of Placebo MDI on Cardiovascular Hemodynamics following chronic-dosing (7 days) in subjects with moderate to severe COPD.

03

Conditions studied

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 40 years of age and no older than 80 at Visit 1.
  • Women of non-child bearing potential,or negative serum pregnancy test at Screening, and agrees to acceptable methods used consistently and correctly from Screening until 14 days after final visit
  • Evidence of lung hyperinflation
  • Subjects with an established clinical history of as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS)
  • Current or former smokers with a history of at least 10 pack-years of cigarette smoking.
  • Pre- and Post-bronchodilator /FVC ratio must be \<0.70
  • Post-bronchodilator FEV1 must be ≥30% to \<65% predicted normal value, calculated using NHANES III reference equations.

Exclusion criteria

Exclusion Criteria:

  • Significant diseases or conditions other than which, in the opinion of the Investigator, may put the patient at risk
  • Women who are pregnant or lactating or are planning to become pregnant during the course of the study
  • Subjects, who in the opinion of the Investigator, have a current diagnosis of asthma or other active pulmonary disease
  • Subjects who have been hospitalized due to poorly controlled COPD within 3 months prior to Screening
  • Subjects who have poorly controlled COPD, defined as acute worsening of COPD that requires treatment with oral or antibiotics within 6 weeks prior to Screening or during the Screening Period
  • Subjects who have uncontrolled hypertension.
  • Subjects with symptomatic prostatic hypertrophy that is clinically significant and not adequately controlled with appropriate therapy, in the opinion of the Investigator.
  • Subjects with bladder neck obstruction or urinary retention that is clinically significant in the opinion of the Investigator.
  • Subjects with a calculated ≤30 mL/minute using Chronic Kidney Disease Epidemiology Collaboration. () formula at Screening and on repeat testing prior to Visit 2.
  • Subjects with abnormal liver function tests defined as , ALT, or total ≥ 1.5 times at Screening and on repeat testing prior to Visit 2
  • Subjects who have cancer that has not been in complete remission for at least five years.
  • Subjects with a diagnosis of glaucoma, who in the opinion of the Investigator, have not been adequately treated.
  • Subjects with a clinically significant
  • Subjects who were previously enrolled in any previous PT001, PT003, or PT005 study conducted or sponsored by Pearl.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    GFF MDI (PT003)

    Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)

    Drug: GFF MDI (PT003)

  • Placebo comparator
    Placebo MDI

    Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol

    Drug: Placebo MDI

Interventions

  • DrugGFF MDI (PT003)

    Drug pages: Glycopyrrolate · Formoterol

    Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)

  • DrugPlacebo MDI

    Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Right Ventricular End Diastolic Volume Index (RVEDVi) at 2-3 Hours Post-dose on Day 8

    Assessment of right ventricular (RV) volume was performed using magnetic resonance imaging (MRI) using RV end diastolic volume (RVEDV), 2-3 hours after dosing on Day 8 of each treatment period. RVEDV was normalized to body surface area (BSA) to provide the indexed counterpart (RVEDVi). Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

    Time frame: Baseline and Day 8 of either treatment period 1 or 2, as applicable.

Secondary outcomes

  1. Change From Baseline in Aortic Left Ventricular Stroke Volume (LVSV) at 2-3 Hours Post-dose on Day 8

    Assessment of LVSV was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

    Time frame: Baseline and Day 8 of either treatment period 1 or 2, as applicable.

  2. Change From Baseline in Right Ventricular Stroke Volume (RVSV) at 2-3 Hours Post-dose on Day 8

    Assessment of RVSV, phase contrast from pulmonic valve, was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

    Time frame: Baseline and Day 8 of either treatment period 1 or 2, as applicable.

  3. Change From Baseline in Pulmonary Artery Velocity at 2-3 Hours Post-dose on Day 8

    Assessment of Pulmonary Artery Velocity was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

    Time frame: Baseline and Day 8 of either treatment period 1 or 2, as applicable.

  4. Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVi) at 2-3 Hours Post-dose on Day 8

    Assessment of left ventricular (LV) volume was performed using MRI using LV end diastolic volume (LVEDV), 2-3 hours after dosing of Day 8 of each treatment period. LVEDV was normalized to BSA to provide the indexed counterpart (LVEDVi). Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

    Time frame: Baseline and Day 8 of either treatment period 1 or 2, as applicable.

  5. Change From Baseline in Cardiac Output at 2-3 Hours Post-dose on Day 8

    Assessment of cardiac output was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

    Time frame: Baseline and Day 8 of either treatment period 1 or 2, as applicable.

  6. Change From Baseline in Pulmonary Vascular Resistance (PVR) at 30 and 60 Minutes Post-dose on Day 8

    Assessment of PVR was performed by impedance cardiography at 30 and 60 minutes after dosing on Day 8 of each treatment period. Baseline for was defined as the average of the subject values obtained pre-dose on Day 1 of each treatment period.

    Time frame: Baseline and Day 8 of either treatment period 1 or 2, as applicable.

  7. Change From Baseline in Pulmonary Artery/Aortic Diameter Ratio (PA:A) at 2-3 Hours Post-dose on Day 8

    Assessment of PA:A was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

    Time frame: Baseline and Day 8 of either treatment period 1 or 2, as applicable.

  8. Change From Baseline in Left Atrial End Diastolic Volume (LAEDV) at 2-3 Hours Post-dose on Day 8

    Assessment of LAEDV was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

    Time frame: Baseline and Day 8 of either treatment period 1 or 2, as applicable.

  9. Change From Baseline in Left Atrial End Systolic Volume (LAESV) at 2-3 Hours Post-dose on Day 8

    Assessment of LAESV was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

    Time frame: Baseline and Day 8 of either treatment period 1 or 2, as applicable.

  10. Change From Baseline in Left Atrial Ejection Fraction (LAEF) at 2-3 Hours Post-dose on Day 8

    Assessment of LAEF was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

    Time frame: Baseline and Day 8 of either treatment period 1 or 2, as applicable.

  11. Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVi) at 2-3 Hours Post-dose on Day 8

    Assessment of LV volume was performed using MRI using LV end systolic volume (LVESV), 2-3 hours after dosing on Day 8 of each treatment period. LVESV was normalized to BSA to provide the indexed counterpart (LVESVi). Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

    Time frame: Baseline and Day 8 of either treatment period 1 or 2, as applicable.

  12. Change From Baseline in Right Ventricular End Systolic Volume Index (RVESVi) at 2-3 Hours Post-dose on Day 8

    Assessment of RV volume was performed using MRI using RV end systolic volume (RVESV), 2-3 hours after dosing on Day 8 of each treatment period. RVESV was normalized to BSA to provide the indexed counterpart (RVESVi). Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

    Time frame: Baseline and Day 8 of either treatment period 1 or 2, as applicable.

  13. Change From Baseline in Pulsatility Index Aorta (PIAo) at 2-3 Hours Post-dose on Day 8

    Assessment of PIAo was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

    Time frame: Baseline and Day 8 of either treatment period 1 or 2, as applicable.

  14. Change From Baseline in Pulmonary Artery Pulsatility Index (PAPi) at 2-3 Hours Post-dose on Day 8

    Assessment of PAPi was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

    Time frame: Baseline and Day 8 of either treatment period 1 or 2, as applicable.

07

Results

Posted Aug 28, 2019
Limitations and caveats
This study was terminated early on 20 June 2018 as target enrollment numbers were not met.

Participant flow

Subjects with moderate to severe chronic obstructive pulmonary disease (COPD) were enrolled into this 2-period, 2-treatment, crossover study from 09 December 2016. The study was terminated early on 20 June 2018.

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneGFF MDI, Then Placebo MDIPlacebo MDI, Then GFF MDI
Started13
Completed13
Not completed00
Washout Period
Participant flow — Washout Period
MilestoneGFF MDI, Then Placebo MDIPlacebo MDI, Then GFF MDI
Started13
Completed13
Not completed00
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneGFF MDI, Then Placebo MDIPlacebo MDI, Then GFF MDI
Started13
Completed13
Not completed00

Outcome measures

PrimaryChange From Baseline in Right Ventricular End Diastolic Volume Index (RVEDVi) at 2-3 Hours Post-dose on Day 8

Assessment of right ventricular (RV) volume was performed using magnetic resonance imaging (MRI) using RV end diastolic volume (RVEDV), 2-3 hours after dosing on Day 8 of each treatment period. RVEDV was normalized to body surface area (BSA) to provide the indexed counterpart (RVEDVi). Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

Time frame:
Baseline and Day 8 of either treatment period 1 or 2, as applicable.
Reported as:
Mean · cm^3/m^2
Change From Baseline in Right Ventricular End Diastolic Volume Index (RVEDVi) at 2-3 Hours Post-dose on Day 8
cm^3/m^2GFF MDIPlacebo MDI
Change From Baseline in Right Ventricular End Diastolic Volume Index (RVEDVi) at 2-3 Hours Post-dose on Day 86.10 ± 7.69-7.93 ± 8.64
SecondaryChange From Baseline in Aortic Left Ventricular Stroke Volume (LVSV) at 2-3 Hours Post-dose on Day 8

Assessment of LVSV was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

Time frame:
Baseline and Day 8 of either treatment period 1 or 2, as applicable.
Reported as:
Mean · cm^3
Change From Baseline in Aortic Left Ventricular Stroke Volume (LVSV) at 2-3 Hours Post-dose on Day 8
cm^3GFF MDIPlacebo MDI
Change From Baseline in Aortic Left Ventricular Stroke Volume (LVSV) at 2-3 Hours Post-dose on Day 88.40 ± 14.142.88 ± 12.61
SecondaryChange From Baseline in Right Ventricular Stroke Volume (RVSV) at 2-3 Hours Post-dose on Day 8

Assessment of RVSV, phase contrast from pulmonic valve, was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

Time frame:
Baseline and Day 8 of either treatment period 1 or 2, as applicable.
Reported as:
Mean · cm^3
Change From Baseline in Right Ventricular Stroke Volume (RVSV) at 2-3 Hours Post-dose on Day 8
cm^3GFF MDIPlacebo MDI
Change From Baseline in Right Ventricular Stroke Volume (RVSV) at 2-3 Hours Post-dose on Day 88.38 ± 12.742.83 ± 12.40
SecondaryChange From Baseline in Pulmonary Artery Velocity at 2-3 Hours Post-dose on Day 8

Assessment of Pulmonary Artery Velocity was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

Time frame:
Baseline and Day 8 of either treatment period 1 or 2, as applicable.
Reported as:
Mean · cm/second
Change From Baseline in Pulmonary Artery Velocity at 2-3 Hours Post-dose on Day 8
cm/secondGFF MDIPlacebo MDI
Change From Baseline in Pulmonary Artery Velocity at 2-3 Hours Post-dose on Day 80.91 ± 1.67-0.15 ± 1.43
SecondaryChange From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVi) at 2-3 Hours Post-dose on Day 8

Assessment of left ventricular (LV) volume was performed using MRI using LV end diastolic volume (LVEDV), 2-3 hours after dosing of Day 8 of each treatment period. LVEDV was normalized to BSA to provide the indexed counterpart (LVEDVi). Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

Time frame:
Baseline and Day 8 of either treatment period 1 or 2, as applicable.
Reported as:
Mean · cm^3/m^2
Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVi) at 2-3 Hours Post-dose on Day 8
cm^3/m^2GFF MDIPlacebo MDI
Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVi) at 2-3 Hours Post-dose on Day 86.95 ± 6.47-1.77 ± 6.44
SecondaryChange From Baseline in Cardiac Output at 2-3 Hours Post-dose on Day 8

Assessment of cardiac output was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

Time frame:
Baseline and Day 8 of either treatment period 1 or 2, as applicable.
Reported as:
Mean · Liters/minute
Change From Baseline in Cardiac Output at 2-3 Hours Post-dose on Day 8
Liters/minuteGFF MDIPlacebo MDI
Change From Baseline in Cardiac Output at 2-3 Hours Post-dose on Day 80.95 ± 0.800.38 ± 1.17
SecondaryChange From Baseline in Pulmonary Vascular Resistance (PVR) at 30 and 60 Minutes Post-dose on Day 8

Assessment of PVR was performed by impedance cardiography at 30 and 60 minutes after dosing on Day 8 of each treatment period. Baseline for was defined as the average of the subject values obtained pre-dose on Day 1 of each treatment period.

Time frame:
Baseline and Day 8 of either treatment period 1 or 2, as applicable.

No measurements were reported for this outcome.

SecondaryChange From Baseline in Pulmonary Artery/Aortic Diameter Ratio (PA:A) at 2-3 Hours Post-dose on Day 8

Assessment of PA:A was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

Time frame:
Baseline and Day 8 of either treatment period 1 or 2, as applicable.
Reported as:
Mean · ratio
Change From Baseline in Pulmonary Artery/Aortic Diameter Ratio (PA:A) at 2-3 Hours Post-dose on Day 8
ratioGFF MDIPlacebo MDI
Change From Baseline in Pulmonary Artery/Aortic Diameter Ratio (PA:A) at 2-3 Hours Post-dose on Day 8-0.03 ± 0.15-0.04 ± 0.21
SecondaryChange From Baseline in Left Atrial End Diastolic Volume (LAEDV) at 2-3 Hours Post-dose on Day 8

Assessment of LAEDV was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

Time frame:
Baseline and Day 8 of either treatment period 1 or 2, as applicable.

No measurements were reported for this outcome.

SecondaryChange From Baseline in Left Atrial End Systolic Volume (LAESV) at 2-3 Hours Post-dose on Day 8

Assessment of LAESV was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

Time frame:
Baseline and Day 8 of either treatment period 1 or 2, as applicable.

No measurements were reported for this outcome.

SecondaryChange From Baseline in Left Atrial Ejection Fraction (LAEF) at 2-3 Hours Post-dose on Day 8

Assessment of LAEF was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

Time frame:
Baseline and Day 8 of either treatment period 1 or 2, as applicable.

No measurements were reported for this outcome.

SecondaryChange From Baseline in Left Ventricular End Systolic Volume Index (LVESVi) at 2-3 Hours Post-dose on Day 8

Assessment of LV volume was performed using MRI using LV end systolic volume (LVESV), 2-3 hours after dosing on Day 8 of each treatment period. LVESV was normalized to BSA to provide the indexed counterpart (LVESVi). Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

Time frame:
Baseline and Day 8 of either treatment period 1 or 2, as applicable.
Reported as:
Mean · cm^3/m^2
Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVi) at 2-3 Hours Post-dose on Day 8
cm^3/m^2GFF MDIPlacebo MDI
Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVi) at 2-3 Hours Post-dose on Day 82.68 ± 2.56-3.18 ± 2.06
SecondaryChange From Baseline in Right Ventricular End Systolic Volume Index (RVESVi) at 2-3 Hours Post-dose on Day 8

Assessment of RV volume was performed using MRI using RV end systolic volume (RVESV), 2-3 hours after dosing on Day 8 of each treatment period. RVESV was normalized to BSA to provide the indexed counterpart (RVESVi). Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

Time frame:
Baseline and Day 8 of either treatment period 1 or 2, as applicable.
Reported as:
Mean · cm^3/m^2
Change From Baseline in Right Ventricular End Systolic Volume Index (RVESVi) at 2-3 Hours Post-dose on Day 8
cm^3/m^2GFF MDIPlacebo MDI
Change From Baseline in Right Ventricular End Systolic Volume Index (RVESVi) at 2-3 Hours Post-dose on Day 81.92 ± 5.95-9.23 ± 4.64
SecondaryChange From Baseline in Pulsatility Index Aorta (PIAo) at 2-3 Hours Post-dose on Day 8

Assessment of PIAo was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

Time frame:
Baseline and Day 8 of either treatment period 1 or 2, as applicable.
Reported as:
Mean · percent
Change From Baseline in Pulsatility Index Aorta (PIAo) at 2-3 Hours Post-dose on Day 8
percentGFF MDIPlacebo MDI
Change From Baseline in Pulsatility Index Aorta (PIAo) at 2-3 Hours Post-dose on Day 8-0.63 ± 13.45-0.37 ± 4.07
SecondaryChange From Baseline in Pulmonary Artery Pulsatility Index (PAPi) at 2-3 Hours Post-dose on Day 8

Assessment of PAPi was performed using MRI, 2-3 hours after dosing on Day 8 of each treatment period. Baseline was defined as the pre-dose value on Day 1 of treatment period 1.

Time frame:
Baseline and Day 8 of either treatment period 1 or 2, as applicable.
Reported as:
Mean · percent
Change From Baseline in Pulmonary Artery Pulsatility Index (PAPi) at 2-3 Hours Post-dose on Day 8
percentGFF MDIPlacebo MDI
Change From Baseline in Pulmonary Artery Pulsatility Index (PAPi) at 2-3 Hours Post-dose on Day 83.60 ± 10.86-4.95 ± 19.54

Adverse events

Collected over Adverse events were collected from screening, throughout the treatment periods until the follow-up visit 14±2 days from the last study treatment administration. Overall timeframe of up to a maximum of 12 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GFF MDI0/4 (0%)0/4 (0%)0/4 (0%)
Placebo0/4 (0%)0/4 (0%)1/4 (25%)
Most frequent other events
Most frequent other events
EventGFF MDIPlacebo
Skin irritationSkin and subcutaneous tissue disorders0/41/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)All Randomized Subjects
<=18 years0
Between 18 and 65 years2
>=65 years2
Sex: Female, Male
Sex: Female, Male(Participants)All Randomized Subjects
Female2
Male2
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Randomized Subjects
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White3
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Research Site
    Birmingham, Alabama 35294, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AstraZeneca's policy is to share data with researchers if the request is in scope of our policy. The policy and additional information can be found on astrazenecaclinicaltrials.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Jun 2018, 17 months.

Results were first posted in Aug 2019, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2016
First posted
Feb 18, 2016
StartActual
Dec 9, 2016
Primary completionActual
Jun 6, 2018
CompletionActual
Jun 6, 2018
Results first posted
Aug 28, 2019
Last update
Aug 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02685293
Responsible party
Sponsor
First posted
Feb 18, 2016
Start date
Dec 9, 2016
Primary completion
Jun 6, 2018
Completion
Jun 6, 2018
Results posted
Aug 28, 2019
Last update
Aug 28, 2019

Study contacts

Colin Reisner, MD
study chair · Pearl Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glycopyrrolate · Formoterol

Start the discussion